{
  "meta": {
    "timestamp": "2025-01-06T11:37:44.261083",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Glaukos Corp",
      "symbol": "GKOS",
      "analysis": {
        "historical": {
          "risk_score": 50,
          "key_risks": [
            "Regulatory and legal risks, including delays in FDA and international approvals",
            "Market competition in the MIGS sector, potentially pressuring pricing and margins",
            "Reimbursement challenges across different regions",
            "Product liability risks due to the nature of medical devices",
            "Economic and pandemic impacts on elective procedures"
          ],
          "controversies": [
            "Recent settlement of a patent infringement lawsuit with Ivantis, Inc., involving a $60 million payment and ongoing royalties"
          ],
          "environmental_issues": [],
          "social_issues": [
            "Commitment to healthcare compliance and ethical practices, demonstrated by the Comprehensive Compliance Program (CCP)"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 75
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Glaukos - Glaukos Announces Settlement of Patent Litigation with ...",
              "snippet": "Ivantis to Pay $60 Million and Ongoing Double-Digit Royalty to Glaukos Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a settlement agreement with Ivantis, Inc. agreeing to terminate the patent infringement ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518190+00:00",
              "published_date": null,
              "source_hash": "8e4a31878834dc9b327486155f86a20a"
            },
            {
              "url": "",
              "title": "Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.",
              "snippet": "Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that it has filed a patent infringement lawsuit against Ivantis, Inc. in the U.S. District Court for the Central District of California, Southern Division.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518312+00:00",
              "published_date": null,
              "source_hash": "a71e033af5a709a2e0ecc0afee50d214"
            },
            {
              "url": "",
              "title": "Ivantis Announces Settlement of Glaukos Patent Litigation - PR Newswire",
              "snippet": "The parties have also agreed to a mutual limited, non-exclusive cross-license and covenant not to sue each other's existing or closely related products on their existing or related future patents.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518333+00:00",
              "published_date": null,
              "source_hash": "ab1c6bf8f3f717f7745e7175612edfc5"
            },
            {
              "url": "",
              "title": "Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc ...",
              "snippet": "Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518424+00:00",
              "published_date": null,
              "source_hash": "5088836fe533eccf533aa1d9eacbd4a7"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "Plaintiff and Counter-Defendant Glaukos Corporation (\"Glaukos\") moved for an adverse inference instruction and exclusion regarding Defendant Ivantis, Inc.'s (\"Ivantis\") alleged spoliation of evidence. Mot., Dkt. No. 413 (sealed version at Dkt. No. 429-7). Ivantis opposed. Opp'n, Dkt. No. 495 (sealed version at Dkt. No. 509). Glaukos ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518438+00:00",
              "published_date": null,
              "source_hash": "62aceabf95a49b123e3a44ae77aa0036"
            },
            {
              "url": "",
              "title": "Glaukos Files Patent Infringement Lawsuit Against Ivantis, Inc.",
              "snippet": "For Glaukos Corporation Media Contact: Cassandra Dump (619) 971-1887 cassy@pascalecommunications.com or Investor Contact: Chris Lewis Director, Investor Relations, Corporate Development & Strategy ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518451+00:00",
              "published_date": null,
              "source_hash": "c23e97d72d67d84b9ece1e15cc51f9e9"
            },
            {
              "url": "",
              "title": "Glaukos, Ivantis settle patent lawsuit - Healio",
              "snippet": "Glaukos and Ivantis have entered into a settlement agreement to terminate a patent infringement lawsuit concerning the Hydrus microstent, according to company press releases.Ivantis will pay ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518464+00:00",
              "published_date": null,
              "source_hash": "cd589401a69cb1ce30ede81f95952661"
            },
            {
              "url": "",
              "title": "Glaukos in Patent Litigation Settlement With Ivantis - Bloomberg Law News",
              "snippet": "Ivantis will also pay Glaukos a 10% ongoing royalty through April 26, 2025; Parties will submit a joint request to stay the pending litigation, which had been scheduled for trial beginning on September 28, 2021, and dismiss it upon receipt of the first upfront payment; Glaukos shares down 33.54% YTD vs S&P Smallcap 600 Index up 17.90% YTD",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518477+00:00",
              "published_date": null,
              "source_hash": "6e48afb07818413317f90046cd3bf602"
            },
            {
              "url": "",
              "title": "Ivantis To Pay $60M In Patent Litigation Settlement With Glaukos",
              "snippet": "Glaukos Corp (NYSE: GKOS) has settled a patent infringement lawsuit with Ivantis Inc. The lawsuit was initiated by Glaukos in 2018 in the U.S. District Court for the Central District of California ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518491+00:00",
              "published_date": null,
              "source_hash": "4800853bf84e926a209458323ba8094b"
            },
            {
              "url": "",
              "title": "Glaukos files patent lawsuit against Ivantis - Healio",
              "snippet": "Glaukos Corporation filed a patent infringement lawsuit against Ivantis Inc., according to a company press release.Filed in the U.S. District Court for the Central District of California, Southern ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:14.518504+00:00",
              "published_date": null,
              "source_hash": "2f9d429f7d04220b4b6bbcb799d63900"
            },
            {
              "url": "",
              "title": "Here's Why You Should Add Glaukos Stock to Your Portfolio Now",
              "snippet": "Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:27.166548+00:00",
              "published_date": "2024-12-11T00:00:00+00:00",
              "source_hash": "5dcdc2524d672ec93301e2a3ee13433a"
            },
            {
              "url": "",
              "title": "Glaukos director Gilbert H. Kliman sells shares worth $1.5 million",
              "snippet": "Gilbert H. Kliman, a director at Glaukos Corp (NYSE:GKOS), recently sold 10,000 shares of the company's common stock. The company, with a market capitalization of $8.2 billion, has seen its stock ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:18.049098+00:00",
              "published_date": "2024-12-24T00:55:00+00:00",
              "source_hash": "9e2e77561ffad2ebe4188216a0780da6"
            },
            {
              "url": "",
              "title": "Glaukos Stock Soars 77.9% Year to Date: What's Behind the Rally?",
              "snippet": "Glaukos' revenues outpaced expectations in the first half of 2024, driven by robust product demand. The company registered revenues of $96.7 million in the third quarter, up 23.9% year over year.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:18.049127+00:00",
              "published_date": "2024-12-10T01:05:00+00:00",
              "source_hash": "f55ab337a43a33596ed71cf05bb33e2a"
            },
            {
              "url": "",
              "title": "Glaukos: Q3 Earnings Snapshot",
              "snippet": "ALISO VIEJO, Calif. (AP) \u2014 ALISO VIEJO, Calif. (AP) \u2014 Glaukos Corp. (GKOS) on Monday reported a loss of $21.4 million in its third quarter. The Aliso Viejo, California-based company said it ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp product liability lawsuits",
              "retrieved_at": "2025-01-06T18:37:18.049150+00:00",
              "published_date": "2024-11-04T00:00:00+00:00",
              "source_hash": "500351560baa490979719c4b6d3bdf9e"
            },
            {
              "url": "",
              "title": "Declaration of Compliance - Glaukos",
              "snippet": "As part of our continued efforts in the area of healthcare compliance, Glaukos has developed a Comprehensive Compliance Program (\"CCP\") that is reasonably designed to prevent and detect violations. Consistent with industry practice and various government guidance documents, we have tailored our CCP to the nature of our business as primarily ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.435858+00:00",
              "published_date": null,
              "source_hash": "fc104daceb364c649ed3373240f369d7"
            },
            {
              "url": "",
              "title": "Investors - Governance & Sustainability - Glaukos",
              "snippet": "Contact Us. Glaukos Corporation One Glaukos Way Aliso Viejo, CA 92656. 949-481-0510 Send Email Fax: 949-367-9984",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.435947+00:00",
              "published_date": null,
              "source_hash": "ed9e5888db71a93814ad9b88b6667b18"
            },
            {
              "url": "",
              "title": " Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.",
              "snippet": "About Glaukos Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478543+00:00",
              "published_date": null,
              "source_hash": "f50ca572afbe1306e5ddfc5368e806c0"
            },
            {
              "url": "",
              "title": "How Glaukos Transformed Risk Management With Oracle Cloud - Sikich",
              "snippet": "Thus, Glaukos has effectively strengthened its confidence in its compliance processes and operational performance, enabling the company to proactively manage risks before they escalate. Glaukos plans to enhance its focus on Segregation of Duties compliance while continuing to phase out legacy systems, consolidating risk and compliance processes ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.435978+00:00",
              "published_date": null,
              "source_hash": "5c1144fe7e7ebb87750222850c7b3f5b"
            },
            {
              "url": "",
              "title": "Glaukos - Investors - Governance & Sustainability - Corporate ...",
              "snippet": "Contact Us. Glaukos Corporation One Glaukos Way Aliso Viejo, CA 92656. 949-481-0510 Send Email Fax: 949-367-9984",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.435991+00:00",
              "published_date": null,
              "source_hash": "c1e5166a00c99a734241022923ded8c3"
            },
            {
              "url": "",
              "title": " Glaukos Corporation",
              "snippet": "Compliance Officer or the Board of Directors, as applicable, will work with you to determine whether you have a conflict of interest and, if so, how best to address it. CORPORATE OPPORTUNITIES . As an employee or director of the Company, you have an obligation to advance the Company's interests when the opportunity to do so arises.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.436003+00:00",
              "published_date": null,
              "source_hash": "44d5a1e0ca83d72aa2e2fa6c9262f175"
            },
            {
              "url": "",
              "title": "Glaukos Submits New Drug Application to U.S. FDA for Epioxa",
              "snippet": "ALISO VIEJO - Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Epioxa (Epi-on), its next-generation corneal cross-linking iLink therapy ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.436016+00:00",
              "published_date": null,
              "source_hash": "0b9cd9c38221b2c9c6d4c0fad4875ae4"
            },
            {
              "url": "",
              "title": "Declaration of Compliance | Privacy Policies - Glaukos",
              "snippet": "Declaration Pursuant to California Health and Safety Code \u00a7119402(e) - August 2022. As part of our continued efforts in the area of healthcare compliance, Glaukos has developed a Comprehensive Compliance Program (\"CCP\") that is reasonably designed to prevent and detect violations.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.436030+00:00",
              "published_date": null,
              "source_hash": "a287354d602bd0332b53d514ea34acb8"
            },
            {
              "url": "",
              "title": "Glaukos Corporation hiring Director, Regulatory Affairs-Pharma Job in ...",
              "snippet": "Upload your resume - let employers find you. Glaukos Corporation. 4.5",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.436046+00:00",
              "published_date": null,
              "source_hash": "0a67faace848fd4a7cbee8e3b972eeab"
            },
            {
              "url": "",
              "title": "Regulatory Affairs Specialist II at Glaukos Corporation - The Muse",
              "snippet": "The Regulatory Affairs Specialist II is responsible for preparation of international regulatory submissions. Ensure implementation and maintenance of regulatory filing in compliance with applicable regulations and Glaukos internal SOPs. This individual will review international regulatory requirements and compile submissions accordingly.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:20.436057+00:00",
              "published_date": null,
              "source_hash": "0855c4879991cabfabf0f61a1f49957d"
            },
            {
              "url": "",
              "title": "What 11 Analyst Ratings Have To Say About Glaukos",
              "snippet": "Stay informed and make well-considered decisions with our Ratings Table. Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:27.166571+00:00",
              "published_date": "2024-12-31T14:00:00+00:00",
              "source_hash": "8b46056cad28357edc238842a6923b92"
            },
            {
              "url": "",
              "title": "Glaukos Submits New Drug Application to U.S. FDA for Epioxa\u2122",
              "snippet": "--(BUSINESS WIRE)--Glaukos Corporation (NYSE ... the extent to which we may obtain regulatory approval for Epioxa or other investigational products, our ability to successfully commercialize ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:23.002088+00:00",
              "published_date": "2024-12-23T07:00:00+00:00",
              "source_hash": "152576bf1dfe91cc69259bb53b9eac13"
            },
            {
              "url": "",
              "title": "Glaukos director Klimans sells $288k in stock",
              "snippet": "Gilbert H. Kliman, a director at Glaukos Corp (NYSE:GKOS), recently executed a series of stock transactions, as disclosed in a filing with the Securities and Exchange Commission. The transactions ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:23.002126+00:00",
              "published_date": "2024-12-14T00:52:00+00:00",
              "source_hash": "a439e27f8dcef9d720dae4427e262154"
            },
            {
              "url": "",
              "title": "Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA",
              "snippet": "Glaukos Corporation GKOS recently announced that it has submitted its New Drug Application (NDA) to the FDA for Epioxa. Epioxa is GKOS' next-generation corneal cross-linking iLink therapy for ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Glaukos Corp Glaukos Corp regulatory compliance issues",
              "retrieved_at": "2025-01-06T18:37:23.002294+00:00",
              "published_date": "2024-12-24T17:38:00+00:00",
              "source_hash": "3a86af338c984f566cc1832791727ac2"
            },
            {
              "url": "",
              "title": "Glaukos reports positive Phase 3 results for Epioxa",
              "snippet": "As a reminder, the U.S. FDA has confirmed Glaukos' first Phase 3 pivotal trial for Epioxa, which met the pre-specified primary efficacy endpoint, would be adequate to support the submission and review of an eventual NDA, in conjunction with this second Phase 3 trial. According to the company, it recently completed a successful clinical pre ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478408+00:00",
              "published_date": null,
              "source_hash": "07130fe61ee97a6991c6e0d88ea1f001"
            },
            {
              "url": "",
              "title": "Glaukos Stocks Rides on Strong Product Demand Amid Competition",
              "snippet": "A number of these pipeline programs are in active pivotal clinical trials, including iLution Travoprost, iDose ROCK and iDose TREX. The company's shares have risen 58.2% year to date compared ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478518+00:00",
              "published_date": null,
              "source_hash": "c97a701eb9cf9af0f8d1857d2e618a7d"
            },
            {
              "url": "",
              "title": "Here's Why You Should Retain Glaukos Stock in Your Portfolio Now",
              "snippet": "Glaukos, with a market capitalization of $7.2 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 4% for 2024, followed by 35.6% ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478532+00:00",
              "published_date": null,
              "source_hash": "9fd35c9b67a8e246ea3beea1a37194b9"
            },
            {
              "url": "",
              "title": "Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory ...",
              "snippet": "ALISO VIEJO, Calif., October 16, 2024--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478555+00:00",
              "published_date": null,
              "source_hash": "ecdc5e44514dca4cf4abcc3cdce790f0"
            },
            {
              "url": "",
              "title": "Glaukos eyes FDA approval for ocular therapy after Phase III win",
              "snippet": "This Phase III trial, along with the first Phase III pivotal trial (NCT03442751), will form the basis of the new drug application (NDA) for Epioxa. Glaukos noted that the \"proposed clinical data package is sufficient to support an NDA submission and review\" as part of a pre-NDA meeting with the FDA.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478565+00:00",
              "published_date": null,
              "source_hash": "6afebe37bff9c2772a044108270654dd"
            },
            {
              "url": "",
              "title": "Glaukos - Glaukos Announces Positive Topline Outcomes in Phase 3 ...",
              "snippet": "ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that the second Phase 3 confirmatory pivotal trial for Epioxa\u2122 ( Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478576+00:00",
              "published_date": null,
              "source_hash": "5aa232c31221d439a761ad510a28f474"
            },
            {
              "url": "",
              "title": "Glaukos - Glaukos Announces Positive Clinical Updates for Several ...",
              "snippet": "Commencement of Subject Enrollment in Epioxa\u2122 Phase 3 Confirmatory Trial Promising Phase 2a Results for GLK-301 (iLution - Dry Eye Disease) Support Planned Phase 2b Study to Commence in 2023 Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478593+00:00",
              "published_date": null,
              "source_hash": "c852684ce4815412284baba7563659ad"
            },
            {
              "url": "",
              "title": "Glaukos announces results of two Phase 3 pivotal trials of iDose TR",
              "snippet": "Moreover, the company noted that based on the combined efficacy and safety results from both Phase 3 pivotal trials, Glaukos plans to move forward with its plans for an NDA submission to the U.S. FDA for the slow-release iDose TR model, with an expected FDA review and decision completed by the end of 2023.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478605+00:00",
              "published_date": null,
              "source_hash": "27153ec7ac05e26ed7d77f3a0cef39eb"
            },
            {
              "url": "",
              "title": "Glaukos Corporation Company Profile by CMR",
              "snippet": "Glaukos Corporation Basic Information, Manufacturing Base, Sales Area, and Competitors. Sr. No. I t e m. D escription. 1. Company Name. Glaukos Corporation. 2. Website. ... Clinical Efficacy: Pivotal Trials: iDose TR has demonstrated non-inferiority to topical timolol through 3 months, achieving long-term IOP control.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:24.478615+00:00",
              "published_date": null,
              "source_hash": "69789b1cf915a762baa7209eb16e3e4d"
            },
            {
              "url": "",
              "title": "Glaukos Submits New Drug Application to U.S. FDA for Epioxa\u2122",
              "snippet": "--(BUSINESS WIRE)--Glaukos Corporation (NYSE ... when commercially marketed as compared to their pre-approval clinical trial results. Historical, current and forward-looking sustainability ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:27.166579+00:00",
              "published_date": "2024-12-23T07:00:00+00:00",
              "source_hash": "f155c7e5f869766cbaf00da579f9c9b4"
            },
            {
              "url": "",
              "title": "Glaukos submits NDA to FDA for Epioxa",
              "snippet": "Glaukos submitted an NDA for Epioxa, a novel corneal cross-linking therapy for keratoconus, to the US FDA. Epioxa's Phase 3 trials demonstrated efficacy, safety, and tolerability, achieving primary efficiency endpoints. Epioxa is a next-generation corneal cross-linking iLink therapy for the treatment of keratoconus.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:27.166586+00:00",
              "published_date": "2024-12-23T13:24:00+00:00",
              "source_hash": "85cb5c8c8e85628d40cf2581872806aa"
            },
            {
              "url": "",
              "title": "Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA",
              "snippet": "Glaukos Corporation GKOS recently ... The positive Phase 3 trial results further strengthen the company's growth outlook, making the stock more appealing to investors anticipating future revenue ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Glaukos Corp Glaukos Corp controversies in clinical trials",
              "retrieved_at": "2025-01-06T18:37:27.166592+00:00",
              "published_date": "2024-12-24T17:38:00+00:00",
              "source_hash": "4c32db9bf02549961ab92ae33c4adad2"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Glaukos Corp product liability lawsuits",
              "rationale": "Investigate potential legal risks related to product liability claims",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Glaukos Corp regulatory compliance issues",
              "rationale": "Examine any regulatory challenges or non-compliance incidents",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Glaukos Corp controversies in clinical trials",
              "rationale": "Assess ethical concerns or controversies in the company's clinical trial practices",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T11:37:44.261096",
        "data_confidence": 75,
        "pattern_confidence": null
      }
    }
  ]
}